Life Sciences Archive » May, 2013

Life Sciences - May, 2013

275 articles

• FCPA Powerhouse: Debevoise
• Settlement Approved In Cold Remedy False Ad Suit
• Avanir Sues Sandoz Over Nuedexta Generic
• Tolling Approved In Bayer $100M Sex Bias Suit
• Battle For K-V Pharma Amps Up As Silver Point Boosts Offer
• Judge's Alcon Dismissal Ends Drug Kickback Qui Tam Suit
• Shire, Teva Call Truce In Fight Over Generic ADHD Drug
• State, Federal NECC Tort Cases To Join Meningitis MDL
• Boston Scientific Unit Can't Duck FCA Claims, DQ Blank Rome
• FDA Rejects Endo Testosterone Drug For 3rd Time
• EU Agency Warns Of GSK Epilepsy Drug's Vision Risks
• Baxter Relators Can't Reopen $30M Price Inflation Suit
• Medicare's Future Depends On Health Co. Squeeze: Trustees
• Schering Says FCA Integrilin Kickbacks Suit Doesn't Stick
• Courts Unswayed By Protests Over AG Outside Counsel Hires
• ArthroCare Exec Pleads Not Guilty In $400M Fraud Scheme
• Device Cos. Slam FDA's Overseas Clinical Trial Rule
• Intema Seeks High Court Review Of Nixed Fetal Test Patent
• Merck Investors Can't Use Vioxx News Report In Fraud MDL
• Biotech Firms, Exec Pay $11M To Settle NJ Fraud Suit
• Procurement: The Hidden Path To Maximizing Profits
• FCPA Powerhouse: Davis Polk
• Takeda Sues 3 Rivals Over Planned Heartburn Drug Generics
• Hospira Told To Clean Up Manufacturing Process In India
• NZ's Ebos Inks $888M Deal For Aussie Drug Wholesaler
• K-V Investor Group Bumps Up Ch. 11 Offer To $275M
• Doryx Antitrust Class Cert. Bids Fall Short, Warner Says
• 9th Circ. Ruling Threatens Shoddy Medicare Part D Insurers
• J&J Unit Cleared Of Union's Info Withholding Charges
• 10th Circ. Reverses Zimmer Win In Knee-Implant Injury Suit
• Eli Lilly Sues Perrigo To Block Generic Testosterone Drug
• Bankrupt K-V Settles Texas Medicaid Fraud Suit For $3M Claim
• Amphastar Asks Justices Not To Review Drug Safe Harbor
• And Now A Word From The Panel ...
• Stryker Looks For Quick Coverage Win In Knee Deal Row
• GSK Pays $321M For Swiss Vaccine Developer Okairos
• ArthroCare Exec Wants Conspirators' Names In $400M Fraud
• J&J Unit Can't Stop Ex-Sales Reps From Working For Rival
• FCPA Powerhouse: Crowell & Moring
• Good Faith Clauses Not Just For Show: Del. Supreme Court
• Rotech Shareholders Seek To Undo $30M DIP Order
• FDA Blasted Over Shared Risk Plans For Brand, Generic Cos.
• Merck Loses Bid To Block Outside Attys In Ky. Vioxx Case
• NJ High Court Agrees To Consolidate Bayer's Mirena Cases
• 9th Circ. Backs Class Cert. In Medline Workers' Wage Suit
• Sergeant's Flea-Killer Ads Blocked In Bayer False Ad Suit
• Shire Division Head Says Firm Duped Him Into Taking Job
• AstraZeneca Spends $443M On Lipid Drug Specialist
• FDA Urges Strong Quality Pacts For Drugmakers, Contractors
• Plan B Advocates Don't Grasp FDA Process, 2nd Circ. Told
• FCPA Powerhouse: Cahill Gordon & Reindel
• Bad Birth Control Packaging Led To Pregnancy, Suit Says
• Valeant Puts Up $8.7B For PE-Backed Bausch & Lomb
• A Look At The Patentability Of 3-D Printed Human Organs
• Fed. Circ. Blocks Generic Sales Of AstraZeneca's Pulmicort
• Conceptus Investor Can't Block $1.2B Bayer Acquisition
• Primcogent Files Ch. 11 In Feud With Fat-Zapping Laser Maker
• Lupin Must Produce Generic Info In Warner Chilcott Suit
• JPML Head Judge Explains Why Panel Is More Picky
• 1st Circ. Revives CVS Shareholder Fraud Class Action
• B&L Unit To Pay $34M For Drug Marketing Guilty Plea: DOJ
• Arbitration Bias Claim In Drug Row Premature, Judge Says
• Law360 Names 10 FCPA Powerhouse Firms
• Fresenius Hits Dr. Reddy's With Diprivan IP Suit
• Royalty Gets 68K Shares Of Support For $6.3B Elan Takeover
• Intuitive Not Negligent In Surgery Death, Jury Rules
• USPTO's Patent Term View Oversteps Authority, Drug Co. Says
• Flonase Users Seek Sanctions For Foes Of $35M Antitrust Deal
• DePuy Loses Bid To Toss $8.3M Hip Implant Verdict
• Ex-Smith & Nephew Exec Loses Sanctions Bid In FCA Suit
• Capsule Seller Can't Duck Suit Over Testosterone Claims
• Forest Labs Subpoenaed Over New COPD Inhaler
• Deals Rumor Mill: Valeant, Google, Suntory
• You May Be Liable For Someone Else's Overintoxication
• Vaccine Distributor Antitrust Claims Should Stick, Judge Told
• Watson, Apotex Settle Azilect Patent Infringement Suit
• Cigna Gets Heart Device Coverage Fight Sent To Arbitration
• Ex-Pfizer Counsel Tapped For NJ County Prosecutor Job
• Deals Sizzle, BBQs To Follow For Busy Deal Makers
• FDA Bans Certain Imports From Indian Drugmaker Wockhardt
• Daiichi Sankyo Mulls Legal Action Over Ranbaxy Settlements
• 6th Circuit Takes Wide View Of Liability In Stock Inflation Suits
• How Monsanto Applies To Nonagricultural Biotechnology
• Kramer Settles Fungi-Nail False Ad Suit
• Royalty Pharma Revises Conditions Of $6B Elan Takeover
• Ex-Watson Manager Says Homophobia Concerns Led To Firing
• FDA Panel Clears Merck Insomnia Drug At Lower Dose
• FDA Shows Deft Touch With 1st Mobile App Enforcement
• Test Strip Maker Barred From Using J&J Unit's Logo In Ads
• Fen-Phen User Fairly Denied Extra Benefits, 3rd Circ. Finds
• Pfizer Plans Stock Swap To Exit Thriving Animal Health Biz
• Senate Panel Advances Drug Compounder Oversight Bill
• Nobel To Pay $1.3M To Settle Faulty Implant Suit
• GSK Awarded Up To $200M For Bioterror Drug Program
• The Starstruck Medical Causation Trend
• Biotech Exec Indicted On Charges He Stole Investor Funds
• Novo To Lay Down $700M For Antibiotics Specialist Xellia
• Herbalife Preys On Latinos, Nonprofit Tells FTC
• Jury Convicts Atty Over Stock Fraud Scheme With Ex-NFLer
• Herbalife Taps PwC As Auditor After KPMG Insider Scandal
• Whistleblower Takes Takeda FCA Case To Supreme Court
• Boehringer, Hospira Products Adulterated, FDA Warns
• Deals Rumor Mill: Dish, Alere, Raytheon
• Reps. Urge Delay Of Medicare Competitive Bidding Program
• Judge Disqualifies Whistleblowers' Attys In Kinetic FCA Suit
• Digging Into The Duty To Mine Big Data
• Pfizer Can't Shake Skelaxin Pay-For-Delay MDL
• High Court Could Put Patent Burden Of Proof On Licensees
• Fighting Agencies May Be Tougher After High Court Ruling
• High Court's Atty Fee Ruling May Spur More Vaccine Claims
• Plan B Ruling Shouldn't Be Stayed, 2nd Circ. Told
• FDA Airs Safety Concerns About Merck Insomnia Drug
• Fed. Circ. Revives 5 Mylan Drug Patents In Sunovion Row
• Fed. Circ. Flips Noninfringement Judgment In Allegra IP Row
• Agencies Deserve Deference On Jurisdiction, Justices Say
• Zydus Defends Obvious Challenge In Zegerid Patent Row
• Dental-Care Company Infringes Crest Patents, P&G Says
• Royalty Pharma Ups Hostile Bid To $6.3B As Elan Maneuvers
• Omnicare Gets FCA Off-Label Prescription Action Trimmed
• High Court Takes Up Medtronic Patent Burden Of Proof Case
• Actavis Puts Up $8.5B For Warner Chilcott
• High Court Takes On Declaratory Judgment Burden Of Proof
• Hedge Fund Sues For Proxy Fight Rematch With Digirad
• MLB Suit Over Performance Boosters Falls Flat, Clinic Says
• Drug Co. Scores Partial Win In Suit Over Botched Offering
• Criminal Probes Await Top Health Cos.: Ex-DOJ Fraud Chief
• AbbVie Targets Hetero Over Generic Norvir Plans
• Pa. Appeals Court To Reconsider $28M Knee Injury Suit
• Rise Of The Machines — Predictive Coding Goes Mainstream
• Obama Budget Would Save $153B In Health Spending: CBO
• Galderma Settles Pimple Drug Patent Suit With Par
• House Dems Seek Tougher Drug Trial Reporting Rules
• European Panel OKs Bayer Acne Drug For Some Women
• FDA Details Approach To Expedited Medical Device Reviews
• GSK Says Comcast Ruling Kills Avandia Injury Class Action
• Steptoe Nabs Trio Of Patent Litigators For Chicago Office
• Allergan Targets Strides, Agila Over Generic Eye Drops
• The Growing Problem Of Fishy Labeling
• J&J To Stop Selling Metal Hips, Facing Thousands Of Suits
• Purdue Puts Generic OxyContin Suits To Rest
• 5 Steps To Take Now For A Successful Recall Later
• J&J Unit Wants Ban On Rival's Use of IP, Logos in Ads
• Axiom Wins Sanctions In Medical Device Trademark Row
• Medical Supplier BestMed Dodges $3.5M Verdict In IP Row
• Athena Blasts Allergan's Competition Claims In Eyelash Fight
• Harvard Can't Reverse USPTO On Mouse-Testing Patent
• Endo Claims Teva, Others Infringe Uncrushable Opana IP
• FDA Details Appeals Process For Rejected Medical Devices
• J&J's S. Korean Unit Faces Charges After Tylenol Recall
• J&J Units Sued Over Spine Implant Patent
• Biolitec Wants Judge Booted In AngioDynamics Row
• Panel Sends Drug-Tracking Bill To House Floor
• FDA Needs To Revamp Benefit-Risk Analysis, Drugmakers Say
• Obama's 1st Term Rulemaking Rate Soars By Bush's Mark
• Lawmakers Forge Ahead On Drug Compounder Oversight Bill
• CMS Sued Over Medicare Prosthetics Payment Rule
• FDA Eases Up On 'Smart Pills' For Wireless Monitoring
• Mass Tort For Tylenol Liver Injuries Requested In NJ
• Rotech Bondholders Want Baker & McKenzie Fees Capped
• Bayer Hits Par With Patent Suit Over Staxyn Generic
• FDA Tells DC Circ. KV Drug Compounding Wasn't A Priority
• Dissident Quigley Creditors Now Support Ch. 11 Plan
• Novartis Wins Jury Verdict Over Zometa's Bone Death Risk
• K-V Case Tests Limits Of ITC Jurisdiction
• 9th Circ. OKs Revoking Medicare Part D Insurer's Contract
• Suit Over Novartis Drug's Bone Death Risk Heads To Jury
• FDA Approves Lower Doses For Sleep Aids
• 3M Infringes Self-Sticking Bandage Patent, Suit Alleges
• Boston Scientific's UK Arm Hit With German Stent Sale Ban
• Genzyme Investors Urge 1st Circ. To Revive Fraud Action
• Pain Patch Maker Wins Coverage Of False Ad Suit
• 2nd Circ. Upholds Standard For SEC Debarment Of Officers
• Sanofi Fined $53M In France Over Generic Plavix Smears
• Shook Hardy Lands Stradley Ronon Life Sciences Whiz
• Get Ready For Stricter RMP Enforcement
• Kasowitz Lures Fish & Richardson IP Atty In Silicon Valley
• AstraZeneca Sues Actavis Over Planned Generic Vimovo
• NJ Court Won't Revive Sun Pharma's Contract Breach Suit
• CR Bard Pays $48M To Settle FCA, Kickback Claims
• CVS, Cardinal Health Returned Opened Drugs, Savient Says
• Teva Defends IP Suit Over Generic MS Drug Research
• Novartis Tells High Court State Punitive Awards Are Illegal
• AGs Urge FDA To Warn Of Newborn Opioid Withdrawal
• Thermo Fisher Hid Mexico Plant's Cartel Woes, OpenGate Says
• Nobel Biocare $1.3M Dental Impact Settlement Stalls
• Ranbaxy Pays Record $500M To End Tainted Drug Claims
• Vitamin C Classes Blast Bid To Nix $153M Antitrust Verdict
• Fired Exec Says Research Firm Illegally Tracked Applicants
• Elan's $1B Royalty Buy Beefs Up Hostile Takeover Defense
• Actavis, Warner Chilcott In Merger Talks
• Drug Cos. See Path To Legal Off-Label Marketing
• Star Scientific Shareholders Sue Over Drug Claims
• Teva Pushes Fed. Circ. To Revive Seasonique Patent Suit
• Robotic Surgery Part May Burn Patients, Intuitive Warns
• Genentech Patent Win Can't Halt Foreign Arbitration
• NECC Dodged Patient-Specific Compounding Rule, Docs Say
• Aveo Hid Kidney Drug's Higher Death Risk, Shareholder Says
• NY Judge Rejects Delay Of Wider Plan B Access
• Novartis Expert Denies Zometa Caused Bone Death In NJ Trial
• LCD Cases May Give Drug Cos. Gold Ticket Out Of State Court
• Arthrocare Exec Cops To $400M Securities Fraud Scheme
• Lawmakers Press Supplement Cos. About DMAA Sales
• Abbott, AbbVie Hit With $2.2M Verdict In Humira Suit
• Allergan Asks Fed. Circ. To Revive Pinkeye Patent Suit
• Shire Blocks Actavis' Generic Lialda Until 2020
• Device Co. Didn't Infringe UV Sterilization Patents, Judge Says
• Compounder Oversight Bill Needs Tweaks, FDA Official Says
• Merck's 'Boys Club' Targeted In $100M Gender Bias Suit
• B. Braun Faces Patent Suit Over Medical Infusion Devices
• Seyfarth Shaw Atty Ducks Sanctions For Missed Conference
• Dissecting The Rules Of Generic Drug User Fee Amendments
• E-Discovery In The Cloud: Who Can Get Your Data?
• Celgene Loses Sanctions Bid Against Teva Unit In Patent Row
• House Panel Approves Prescription Drug Tracking Bill
• K-V Pharma Gets More Time To Hammer Out Ch. 11 Plan
• Bill Would Put Squeeze On FDA Over Antibiotic Resistance
• Abbott, AbbVie Should Pay $5.8M In Humira Suit, Jury Told
• AbbVie, Teva Pay-For-Delay Deal Draws More Antitrust Claims
• ArthroCare Faces DOJ Investigation Over Billing Practices
• 5 Reasons For Optimism In The Venture Capital Community
• Deals Rumor Mill: Sprint, Bain Capital, Bankia
• Icahn Boosts Herbalife Stake Amid Battle For Co.'s Future
• Bristol-Myers Seeks To Bust Genentech Cancer Drug Patents
• Mannatech Sytematically Ousted Female Execs, Ex-VP Says
• CoreValve Asks High Court To Define Patent Enablement
• Canadian Health Officials Hushed Drug Research, Suit Says
• Minn. Appeals Court Revives Drug Overcharge Class Action
• Jones Day Nabs Former Greenberg Life Sciences Litigator
• Judge Slams HHS Over Plan B 'Administrative Filibuster'
• Alcon Urges Dismissal Of Drug Bottle Size Class Action
• Whistleblowers Say DaVita Abusing Doc Privilege In FCA Case
• Preparing A Successful Daubert Motion
• Lessons From Philips FCPA Settlement Over Polish Bribes
• Plan B Ruling's Supporters Urge Judge To Reject Stay
• Stryker, Smith & Nephew Sued Over Bone Plate Patent
• CVS Stops Some Prescription Reminders, Citing HIPAA Update
• Jury Finds Cellectis Patent Claims Against Rival Invalid
• Biomet Accused Of Breaking Patent Deal
• Humira Risks Were Known Before Abbott Letter, Doc Says
• Cancer Drug Kadcyla Must Be Called By Full Name, FDA Says
• Vitacost Beats Suit Over Pre-IPO Disclosures In 11th Circ.
• Punitive Damage Claims Kept Alive In NuvaRing Bellwethers
• Chum Of Ex-Orioles Player Dodges Insider Trading Charges
• Abbott Followed FDA Rules On Humira Updates, Jury Hears
• Ex-Frontier Chemist Dodges Prison For Disclosing Recipes
• Illumina Fails To Shred Syntrix DNA Patent After $96M Verdict
• Kilpatrick Lures Medical IP Vet Back From Industry Role
• 11th Circ. Denies Cert. Appeal In $867M Astellas Antitrust Suit
• K-V Pharma Will Pursue Investors' Alternative Ch. 11 Plan
• FDA Stings Gilead For Manufacturing Violations
• CORRECTED: Judge Pads Stryker's $4.5M Interest Award In Knee Suit
• Pfizer Unit Beats RICO Claims In Skelaxin Pay-For-Delay Row
• Novartis Safety Efforts Challenged In NJ Zometa Trial
• Pharma Cos. Smell Victory In Push For Drug-Tracking System
• Mintz Levin Adds Goodwin IP Atty, WilmerHale Securities Pro
• Apotex's Planned Angiomax Generic Spurs Patent Suit
• Biotech King Gets 4 Years For Stock Manipulation
• Royalty Will Go No Higher In Bid For Elan, Citing J&J Sell-Off
• Fed. Circ. Upholds Most Patents For Allergan Glaucoma Drug
• Pa. Can't Hog Fee Award From Vioxx Settlement, Judge Says
• Appriva Investors Win $250M Jury Award In Contract Fight
• Feds Will Appeal Ruling On Morning-After Pill
• Takeda Ditches $6M Award Linking Diabetes Drug To Cancer
• Novartis Stresses FDA Approvals In Zometa Trial
• Pharma Co. Sues K&L Gates Over Bungled Stock Offering
• High Court Asked To Review 2nd Circ. Fosamax Ruling
• Medicare Board Won't Be Triggered Until 2015, Expert Says
• KV Pharma Can't Duck Securities Suit Over FDA Woes
• Kinetic Wants To DQ Whistleblowers' Attys Over Misused Docs
• NuVasive, Biosystems Settle Noncompete Dispute
• FDA Ignores Toxic Arsenic In Animal Feed, Suit Says
• Generics Co. Rips Novartis' Bid To Combine Reclast Suits
• AbbVie, Teva Hit With 2 More Niaspan Pay-For-Delay Suits
• Deals Rumor Mill: Yahoo, Bain Capital, Fin
• How HIPAA Marketing And Sale Provisions May Apply To You